[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-myeloid-leukemia-cml\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-myeloid-leukemia-cml":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,50,84,124,167,187,213,232],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100555626","phase-2-open-label-study-of-asciminib-for-cml-cp-or-cml-ap-patients-with-t315i-mutation-who-are-resistant-intolerant-or-ineligible-to-ponatinib-100555626",false,"NCT06514534","Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.","A Phase II, Multi-center, Prospective, Open-label Study of Asciminib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP) With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.","ASC4TARGET","Inclusion Criteria:\n\n* Signed informed consent must be obtained prior to participation in the study.\n* Male or female participants with a diagnosis of CML-CP or CML-AP ≥ 18 years of age.\n* Patients with CML-CP or CML-AP with history of documented T315I mutation after at least one TKI and are resistant, intolerant, or ineligible to ponatinib (according to Investigator judgment)\n* Not already treated with asciminib or another any allosteric TKI\n* Failure (adapted from the 2020 \\& 2013 ELN Guidelines) or intolerance to Ponatinib at the time of Screening.\n* Ineligible to ponatinib according to Investigator (based on EU ponatinib SmPC)\n* Evidence of typical BCR::ABL1 transcript or atypical transcripts at the time of Screening which are amenable to standardized or non-standardized RQ-PCR quantification.\n\nExclusion Criteria:\n\n* Previous hematopoietic allogeneic stem-cell transplantation\n* Cardiac or cardiac repolarization abnormality\n* Severe and\u002For uncontrolled concurrent medical disease that in the opinion of the Investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, pulmonary hypertension)\n* History of clinical acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis (except if ponatinib-induced and completely resolved at time of Screening)\n* History of acute or chronic liver disease (i.e., cirrhosis; liver impairment)\n* Known presence of significant congenital or acquired bleeding disorder unrelated to cancer\n* History of other active malignancy within 3 years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively\n* Known history of Human Immunodeficiency Virus (HIV), chronic Hepatitis B Virus (HBV), or chronic Hepatitis C Virus (HCV) infection. Testing for Hepatitis B surface antigen (HBs Ag) and Hepatitis B core antibody (HBcAb \u002F anti HBc) will be performed at Screening\n* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery)\n* Treatment with medications that meet one of the following criteria and that cannot be discontinued at least one week prior to the start of treatment with study treatment:\n\n  * Moderate or strong inducers of CYP3A\n  * Moderate or strong inhibitors of CYP3A\n* Pregnant or nursing (lactating) women\n* Women of child-bearing potential\n* Compound mutant T315I resistant to asciminib monotherapy (polyclonal ABL1 mutations including T315I can be enrolled) Other protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","18 Years","99 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The objective of this Phase II study is to assess the potential of asciminib in managing CML-CP or CML-AP in patient carrying the T315I mutation. The presence of this mutation introduces treatment difficulties due to the limited available options. The study seeks to collect additional data on the effectiveness and safety of asciminib for these patients. By determining the drug's capacity to manage the disease and enhance patients outcomes, the study is designed to fill the unmet medical need and potentially offer a new therapeutic path for patients at a treatment deadlock.",[28],"Chronic Myeloid Leukemia (CML)",[30,31,32,33,34,35,36],"Asciminib","ABL001","Abelson proto-oncogene (ABL1)","Chronic Myelogenous Leukemia (CML)","BCR::ABL1","Phase II","Tyrosine kinase inhibitor (TKI)","RECRUITING","2026-04-17",{"date":40,"type":41},"2026-04-21","ACTUAL",{"date":43,"type":41},"2025-02-18",{"date":45,"type":22},"2029-02-18",{"name":47,"class":48},"Novartis Pharmaceuticals","INDUSTRY",6,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":70,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100616220","phase-1-tacrolimus-targeted-immunosuppression-cessation-in-allogeneic-hct-100616220","NCT07302776","TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT","TACTICAL: TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT","Inclusion Criteria:\n\n* Eligible diseases:\n\n  * Acute myeloid leukemia (AML) in complete remission (CR), CR with incomplete hematologic recovery (CRi), or MLFS.\n  * Myelodysplasic syndrome (MDS) myelodysplastic syndromes eligible for alloHSCT based on IPSS-M of intermediate or higher, or IPSS-R of intermediate or higher, or refractory disease to standard growth factor or hypomethylating agent-based therapy\n  * Myelofibrosis (MF)\n  * Chronic myeloid leukemia (CML) in chronic phase with a prior history of accelerated phase or blast crisis or CML in chronic phase refractory to standard TKI therapy\n  * Chronic myelomonocytic leukemia (CMML)\n* Age ≥ 18 and ≤ 80 years at the time of enrollment.\n* Planned for first myeloablative or reduced intensity allogenic transplant using a conditioning regimen listed in Appendix B.\n* Has a related or unrelated donor available who is 8\u002F8 HLA match at HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods.\n* Estimated glomerular filtration rate (eGFR) ≥ 50 mL\u002Fminute or creatinine \\\u003C 2 mg\u002FdL.\n\nCardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA).\n\n* Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥ 50%.\n* Total bilirubin \\\u003C 2 times upper limit of normal (ULN) (patients with Gilbert's syndrome may be included once hemolysis has been excluded).\n* Karnofsky Performance Score ≥70%\n* Negative serum or urine beta-HCG test in females of childbearing potential (FCBP) within 3 weeks of enrollment.\n\nA female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).\n\n-Ability to understand and the willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Prior allogeneic HCT.\n* Planned donor lymphocyte infusion (DLI).\n* Recipient positive anti-donor HLA antibodies against a mismatched allele in the selected donor determined by either:\n\n  1. Positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing), or\n  2. Presence of anti-donor HLA antibody to any of the following HLA loci: HLA-A, -B, -C, -DRB1, -DQB1, -DQA1, -DPB1, or -DPA1, with mean fluorescence intensity (MFI) \\>1000 by solid phase immunoassay.\n* Uncontrolled bacterial, viral, or fungal infections at time of enrollment including known, active tuberculosis infection.\n* Seropositive for HIV-1 or -2, HTLV-1 or -2, Hepatitis B sAg, and\u002For Hepatitis C antibody.\n\n  \\*History of hepatitis B or hepatitis C is permitted if viral load is undetectable per quantitative PCR and\u002For NAT.\n\nKnown allergy or hypersensitivity to planned GVHD prophylactic medications including PTCy, tacrolimus\n\n* Any uncontrolled autoimmune disease requiring active immunosuppressive treatment.\n* Concurrent malignancy diagnosed within 12 months of enrollment, except non-melanoma skin cancers or other early-stage solid tumors that have been curatively resected or treated to curative intent. Patients with history of low grade concurrent blood cancers that are controlled will be eligible.\n* Females of childbearing potential (FCBP) or men who have sexual contact with FCBP unwilling to use effective forms of birth control or abstinence for one year after transplantation.\n\n(FCBP definition: A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).\n\n-Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the recipient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results.\n\n\\* All subject files must include supporting documentation to confirm subject eligibility.","80 Years",{"count":59,"type":22},50,[61],"PHASE1","The purpose of this study is to test the feasibility and safety of early cessation of tacrolimus following allogeneic hematopoietic cell transplantation (HCT). Post-HCT tacrolimus is given to prevent graft-vs-host-disease (GVHD), but with the use of post-transplant cyclophosphamide (PTCy), the modern approach to GVHD prevention, GVHD rates have reduced markedly.",[64,65,66,67,68,28,69],"GVHD","Hematopoietic Cell Transplantation (HCT)","Acute Myeloid Leukemia (AML)","Myelodysplastic Syndromes","Myelofibrosis (MF)","Chronic Myelomonocytic Leukemia (CMML)",[71,72],"Post-Hematopoietic Cell Transplant (HCT) tacrolimus","hematopoietic cell transplantation (HCT)","NOT_YET_RECRUITING","2026-04-14",{"date":38,"type":41},{"date":77,"type":22},"2026-06",{"date":79,"type":22},"2028-02",{"name":81,"class":82},"Stanford University","OTHER",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":94,"briefSummary":96,"conditions":97,"keywords":102,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":83},"100632842","energia-personalized-exercise-program-for-fatigue-in-patients-with-myeloproliferative-neoplasms-and-chronic-myeloid-leukemia-100632842","NCT07518940","ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia","ENERGIA: Exercise in Rare Hematologic Diseases With Individualized and Adapted Management","ENERGIA","Inclusion Criteria:\n\nAge ≥18 years Confirmed diagnosis of myeloproliferative neoplasm (polycythemia vera, essential thrombocythemia, low-risk primary myelofibrosis) or chronic myeloid leukemia according to WHO criteria Clinical and therapeutic stability for at least 8 weeks prior to enrollment Presence of clinically relevant fatigue as assessed by validated disease-specific questionnaires General clinical condition compatible with participation in a supervised exercise program of at least moderate intensity Absence of contraindications to cardiopulmonary exercise testing No participation in structured exercise or rehabilitation programs within the previous 3 months Minimum hematological safety parameters (hemoglobin \\>10 g\u002FdL; platelets \\>100,000 × 10⁹\u002FL) Ability to understand and comply with study procedures Provision of written informed consent\n\nExclusion Criteria:\n\nUnstable cardiovascular conditions (including uncontrolled heart failure, recent myocardial ischemia, symptomatic ventricular arrhythmias, or unexplained syncope) Thrombotic or hemorrhagic events within the previous 3 months Active acute or chronic infections Severe orthopedic or neurological conditions limiting the ability to perform exercise or functional testing Severe systemic diseases (e.g., advanced renal or hepatic failure, active secondary malignancy, uncontrolled psychiatric disorders) Any clinical condition that, in the investigator's judgment, may compromise safety or adherence to the protocol Indication for a primary structured rehabilitation program based on physiatric evaluation",{"count":93,"type":22},25,[95],"NA","This study evaluates whether a personalized, supervised exercise program can improve fatigue and physical function in patients with myeloproliferative neoplasms (MPN) and chronic myeloid leukemia (CML). Although many patients achieve good disease control with modern therapies, they often experience persistent symptoms such as fatigue that significantly affect daily life.\n\nParticipants will take part in a 12-week exercise program that includes aerobic and resistance training, tailored to their individual fitness level and clinical condition. The program consists of two supervised sessions per week, along with additional home-based aerobic activity. Before and after the program, participants will undergo comprehensive assessments, including cardiopulmonary exercise testing, physical function tests, questionnaires on fatigue and quality of life, and blood sample collection.\n\nThe study aims to determine whether this type of exercise program is feasible and safe, and whether it can reduce fatigue and improve physical capacity, quality of life, and biological markers related to inflammation and metabolism. Participants will also be followed after the intervention to evaluate whether the benefits are maintained over time.",[98,99,100,101,28],"Myeloproliferative Disease","Polycythemia Vera","Thrombocythemia Essential","Myelofibrosis, Primary",[103,104,105,106,107,108,109,110,111,112,113,114],"Myeloproliferative Neoplasms;","Chronic Myeloid Leukemia","Exercise Intervention","Cancer-Related Fatigue","Fatigability","Physical Activity","Cardiorespiratory Fitness","Quality of Life","physical exercise","Immunometabolism","Metabolomics","Feasibility","2026-04-01",{"date":117,"type":41},"2026-04-09",{"date":119,"type":22},"2026-08-01",{"date":121,"type":22},"2027-12-31",{"name":123,"class":82},"Carmen Fava",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":146,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100484580","phase-1-a-first-in-human-study-of-hla-partially-to-fully-matched-allogenic-cryopreserved-deceased-donor-bone-marrow-transplantation-for-patients-with-hematologic-malignancies-100484580","NCT05589896","A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","Inclusion Criteria:\n\n* Patient has the ability to provide informed consent according to the applicable regulatory and local institutional requirements\n* Male or female, aged ≥18 and ≤65 years for patients receiving MAC (Regimen A or Regimen B); aged ≥18 and ≤75 years for patients receiving RIC (Regimen C or D)\n* Patient must require allogeneic HCT per the discretion of the treating physician\n* Patient must be high-resolution, HLA partially or fully matched (4-8\u002F8 allele matched at HLA-A, -B, -C, DRB1) to an available Ossium HPC, Marrow product\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Diagnosed with malignant hematologic disease including:\n\n  1. Acute leukemia \\[acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute biophenotypic leukemia (ABL), or acute undifferentiated leukemia (AUL)\\], MDS without fibrosis, or chronic leukemia (CLL, CML) in the first remission or beyond with ≤5% marrow blasts documented by bone marrow assessment and no circulating blasts or extra-medullary disease within 42 days prior to anticipated start of conditioning\n  2. Chemosensitive non-Hodgkin's lymphomas, Hodgkin's lymphoma, or cutaneous T cell lymphomas in the first remission or beyond documented by PET\u002FCT imaging and bone marrow assessment within 42 days prior to anticipated start of conditioning\n* Karnofsky performance status score ≥70% (MAC) or ≥60% (RIC)\n* HCT comorbidity index (HCT-CI) ≤5\n* Adequate organ function defined as:\n\n  1. Cardiac: LVEF at rest ≥40% (RIC) or LVEF at rest ≥45% (MAC)\n  2. Pulmonary: DLCO, FEV1, FVC ≥50% predicted by pulmonary function tests (PFTs). DLCO value may be corrected for hemoglobin.\n  3. Hepatic: total bilirubin ≤2.0 mg\u002FdL, and ALT, AST, and ALP \\\u003C3 x upper limit normal (ULN), unless ALT, AST, and\u002For ALP are disease related\n  4. Renal: SCr within 1.5x normal range for age. If SCr is outside normal range for age, CrCl\\> 60 mL\u002Fmin\u002F1.73m2 must be obtained (measured by 24-hour urine specimen or nuclear glomerular filtration rate (GFR), or calculated GFR)\n\nExclusion Criteria:\n\n* Availability of suitable graft from living donor (defined as 7\u002F8 or 8\u002F8 HLA-matched related or unrelated donors, haploidentical donors, or cord blood donors)\n* Prior autologous or allogeneic HCT\n* Pregnancy or lactation\n* Ongoing treatment with an investigational drug used for disease-related treatment within 5 half-lives of the drug\n* Current uncontrolled bacterial, viral or fungal infection defined as currently taking medication with evidence of progression of clinical symptoms or radiologic findings\n* Any condition(s) or diagnosis, both physical or psychological, or physical exam finding that in the investigator's opinion precludes participation","75 Years",{"count":132,"type":22},12,[61,25],"The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain lymphomas. Patients will either receive myeloablative conditioning or reduced intensity conditioning regimen prior to the transplant. Patients will be followed for 56 days for safety endpoints and remain in follow-up for one year.",[136,137,138,139,140,141,28,142,143,144,145],"Acute Leukemia","Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Acute Biphenotypic Leukemia","Acute Undifferentiated Leukemia","CLL (Chronic Lymphocytic Leukemia)","MDS (Myelodysplastic Syndrome)","Non-Hodgkin Lymphomas","Hodgkins Lymphoma","Cutaneous T Cell Lymphomas (CTCL)",[147,148,17,149,150,151,152,153,154,155,156],"Leukemia","Hematologic Diseases","AML","ABL","AUL","Bone Marrow Transplant","Lymphoma","MDS","CLL","CML","2026-02-20",{"date":159,"type":41},"2026-02-24",{"date":161,"type":41},"2024-08-16",{"date":163,"type":22},"2027-03-31",{"name":165,"class":48},"Ossium Health, Inc.",9,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":83},"100605670","quality-of-life-and-care-organization-of-patients-with-chronic-myeloid-leukemia-in-the-lombardy-hematology-network-100605670","NCT07165535","Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network","Inclusion Criteria:\n\n* Subjects aged 18 years or older.\n* Subjects diagnosed with Chronic Myeloid Leukemia.\n* Subjects diagnosed with CML under care at the hematology outpatient clinics of the 21 REL centers.\n* Subjects followed at the reference hematology center for a minimum of 6 months.\n* Freely given informed consent obtained before the start of the study.\n\nExclusion Criteria:\n\n* Subjects who have not given consent to participate in the study.\n* Subjects who do not meet the inclusion criteria.",{"count":174,"type":22},2000,"OBSERVATIONAL","The primary objective of the study is to assess the impact of the organizational model of the hematology center on the quality of life of patients with CML estimated through standardized tools (EORTC QLQ-30, CML24) and through the patient's opinion regarding aspects of the quality of care.",[28],"2025-09-08",{"date":180,"type":41},"2025-09-10",{"date":182,"type":41},"2025-04-17",{"date":184,"type":22},"2026-05-17",{"name":186,"class":82},"University of Milano Bicocca",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":23,"phases":197,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":4},"100605113","identification-of-bcrabl1-mutations-by-digital-pcr-in-cml-100605113","NCT07158294","Identification of BCR::ABL1 Mutations by Digital PCR in CML","Digital PCR for Deep Sensitivity BCR::ABL1 Mutation Screening in CML","DiP-in-CML","Inclusion Criteria:\n\n* molecularly confirmed diagnosis of BCR::ABL1+ CML;\n* positivity for either e13a2 or e14a2 transcript;\n* age ≥18 years;\n* chronic phase;\n* on therapy with imatinib or 2 GTKIs (dasatinib, nilotinib and bosutinib);\n* candidate to TKI switch because of resistance according to the ELN recommendations OR with a confirmed warning response to 2GTKI therapy according to the ELN recommendations;\n* Signed written informed consent according to ICH\u002FEU\u002FGCP and national local laws.\n\nExclusion Criteria:\n\n* blastic phase;\n* Previous allogeneic transplant or candidate to allogeneic transplant;\n* on treatment with ponatinib or asciminib, investigational TKIs or non-TKI-therapy;\n* switch performed or planned due to intolerance and not to resistance.",{"count":196,"type":22},150,[95],"The goal of this study is to asses the ability of digital PCR (ddPCR) to detect actionable mutations in adult CML patients with failure of TKI therapy. The main objective of the study is it aims to answer is to assess whether ddPCR is at least as effective as NGS in detecting actionable (2GTKI-resistant) mutations.\n\nTo accomplish this aim, samples of participants treated according to clinical practice, will be taken and analyzed for the presence of BCR::ABL1 KD mutations by ddPCR.",[28],[201,202,203],"Failure","Digital PCR","BCR:ABL1 mutation","2025-08-28",{"date":206,"type":41},"2025-09-05",{"date":208,"type":22},"2026-02-01",{"date":210,"type":22},"2029-04-01",{"name":212,"class":82},"Gruppo Italiano Malattie EMatologiche dell'Adulto",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":175,"phases":4,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":4},"100582602","evaluation-of-cd47-do-not-eat-me-signal-expression-in-chronic-myeloid-leukemia-100582602","NCT06865443","Evaluation of CD47, \"Do Not Eat Me\" Signal Expression in Chronic Myeloid Leukemia","Inclusion Criteria:\n\n* age more than 18 years\n* both sex\n* CML patients, who fulfill the WHO 2022 criteria\n\nExclusion Criteria:\n\n* Patients with other haematological neoplasms (ALL,CLL, plasma cell myeloma)","60 Years",{"count":59,"type":22},"Chronic myeloid leukemia is a myeloid neoplasm characterized by the overproduction of mature granulocytes . Cluster of differentiation 47 (CD47) is a membrane protein, which is over-expressed by virtually all cancers and regulates many signaling systems associated with tumor growth and invasion. Following CD47 binding to the inhibitory receptor (signal regulatory protein, SIRPα) on macrophages, the CD47-receptor complex sends a \"do not eat me\" anti-phagocytic signal to prevent phagocytosis . This balance is tipped by cancer cells, which adopt the \"self\" signal and upregulate CD47 expression to evade immune surveillance and subsequent destruction. Elevated expression of CD47 has been observed in ovarian carcinoma cell lines , murine myeloid leukemias , leukemic stem cells and several solid tumors .\n\nFlow cytometry revealed high surface expression of CD47 on 73% of samples collected from the bone marrow of multiple myeloma (MM) patients .\n\nHigh CD47 expression on six different primary effusion lymphoma (PEL) cell lines compared to peripheral blood mononuclear cells (PBMC) was found . Additionally, in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and several non-Hodgkin's lymphoma (NHL) subtypes, increased CD47 expression is correlated with adverse clinical outcomes .\n\nHematological malignancies, even at onset, present with widespread bone marrow and peripheral blood involvement and many are still without effective systemic curative therapies . Most CML patients have deep and durable responses when treated with BCR::ABL1 tyrosine kinase inhibitors, which might be influenced by long-term toxicities during the treatment .\n\nCD47 \"don't eat me signal\" expression not evaluated in CML. the aim of the study To detect CD47 expression by flow cytometry in CML patients. To study the correlation between BCR::ABL1 gene and CD47 expression in CML patients . Evaluation of the role CD47 as predictor of CML patient outcome",[28],"2025-03-04",{"date":225,"type":41},"2025-03-07",{"date":227,"type":22},"2025-05-01",{"date":229,"type":22},"2026-07-01",{"name":231,"class":82},"Assiut University",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":238,"targetDuration":240,"studyType":175,"phases":4,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":258},"100513253","chronic-myeloid-leukemia-cml-real-life-database-100513253","NCT05963061","Chronic Myeloid Leukemia (CML) Real-Life Database","Inclusion Criteria:\n\n* Patient diagnosed for chronic myelocytic leukemia\n\nExclusion Criteria:\n\n* CML allograft without TKI treatment\n* Refusal or inability to sign the consent",{"count":239,"type":22},3500,"30 Years","Establish the largest possible real-life cohort collecting long-term follow-up of a maximum number of CML patients in order to carry out observational studies: epidemiological, identification of subgroups according to their response to treatment, evaluation of new molecules in real life, therapeutic discontinuations, impact of the evolution of recommendations, etc.",[28],[147,244,245,246,247,36,248],"Leukemia, Myeloid","Chronic myeloid leukemia","Chronic, BCR::ABL Positive","Hematologic Malignancies","Targeted therapy","2024-04-05",{"date":251,"type":41},"2024-04-09",{"date":253,"type":41},"2014-04-16",{"date":255,"type":22},"2034-04-16",{"name":257,"class":82},"University Hospital, Clermont-Ferrand",14]